Premium
Carboplatin and etoposide in advanced colorectal carcinoma. A phase II study
Author(s) -
Jeremic Branislav,
Acimovic Ljubisa,
Mijatovic Ljiljana
Publication year - 1993
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19930501)71:9<2706::aid-cncr2820710903>3.0.co;2-4
Subject(s) - medicine , carboplatin , regimen , etoposide , colorectal cancer , carcinoma , cisplatin , fluorouracil , oncology , gastroenterology , phases of clinical research , chemotherapy , surgery , cancer
Background . For advanced colorectal carcinoma, 5‐fluorouracil (5‐FU)–leucovorin is the best therapy available. To improve results, a variety of drugs were added, including cisplatin (CDDP), sometimes with controversial results. The combination of CDDP and etoposide (VP‐16) has shown synergistic activity in other settings. Although VP‐16 alone is considered rather inactive in colorectal carcinoma, the authors believed it was appropriate to evaluate the combination of VP‐16 and carboplatin (CBDCA) in this disease because the newer platinum analogue CBDCA has more limited side effects than the parent compound. Methods . Twenty‐eight patients with advanced colorectal carcinoma were treated with CBDCA (200 mg/m 2 , days 1–3) and VP‐16 (100 mg/m 2 , days 1–5). Cycles were repeated every 4 weeks. All patients received at least two cycles (median, six cycles; range, two to eight cycles). Results . There were three complete responses and four partial responses. The median duration of response was 35 weeks (range, 25–84 weeks). The median time to tumor progression was 23 weeks (range, 9–84 weeks). The median survival time was 49 weeks (range, 9–151 + weeks). Toxic effects generally were assessed as mild, with no Grade 4 (Eastern Cooperative Oncology Group classification) toxic effects observed during this study. Conclusions . Response rate and toxic effects observed during this study warrant additional studies comparing this regimen with 5‐FU–based regimens in advanced colorectal carcinoma.